The basal ganglia is an essential component of the central circuitry controlling voluntary movement as well as sensorimotor integration, motor and non-motor learning, and a number of higher cognitive functions. The major input structure of the basal ganglia is the striatum, comprised mostly of medium sized GABAergic spiny projection neurons (MSNs) that make up about 95% of striatal neurons in the rodent. The remaining neurons consist of cholinergic interneurons and 3 types of GABAergic interneurons. The GABAergic interneurons play a crucial role in striatal function by participating in a powerful feedforward inhibitory circuit that affects spike timing in the spiny neurons. Dopamine (DA), originating in the substantia nigra, has long been recognized to play an essential role in striatal function, and it is the degeneration of the nigrostriatal DAergic pathway that is the cause of Parkinson's disease, a progressive and incurable disorder that affects between 1 and 1.5 million Americans. In addition to the cell types listed above, a population of striatal neurons has been recognized that expresses tyrosine hydroxylase (TH), the rate-limiting enzyme in the synthesis of DA. In primates essentially all of these neurons also express the DA transporter (DAT) suggesting strongly that they are DAergic. These neurons also express glutamate decarboxylase, the enzyme responsible for the synthesis of GABA and a common marker for GABAergic neurons. The numbers of these neurons increases several-fold following DA denervation, and some of these neurons have been shown to express L-amino acid decarboxylase (AADC) and the vesicular monoamine transporter (VMAT). These neurons could represent a heretofore-unappreciated source of striatal DA and a potentially useful source of compensation for DA loss in idiopathic Parkinson's disease as well as a potential target for novel therapeutic approaches to the treatment of the disease. These striatal TH+ neurons represent novel components of the intrastriatal circuitry about which little or nothing is known, since they have never been recorded from, but only studied with immunocytochemistry. We used striatal slices from mice genetically engineered to express enhanced green fluorescent protein (EGFP) under the control of the TH promoter to obtain visually guided recording from these neurons in brain slices. We have identified 4 electrophysiologically distinct subtypes and provide preliminary data on their efferent and afferent synaptic connectivity. Using these mice, both untreated and after unilateral dopaminergic denervation and/or L-DOPA replacement therapy, we will describe the basic electrophysiological properties of striatal DA neurons, their afferent and efferent connectivity, compensatory changes in DA depletion animal models of PD, and their role in striatal DA and GABAergic neurotransmission. In addition, these mice afford a novel way to study the electrophysiological and anatomical properties of uncharacterized populations of striatal interneurons that have been difficult or impossible to study previously in any systematic way.
Parkinson's disease (PD) is the most common neurological disorder, affecting nearly 15% of people over the age of 65 and over 50% of people over the age of 85. This translates to approximately 1.5 million Americans. The disease is progressive and incurable. PD is caused by a loss of dopamine input to the neostriatum, a brain structure that controls voluntary movement. In this project we will characterize electrophysiologically, neurochemically and neuroanatomically novel dopamine-like neurons in the striatum that have the potential to serve as the focal point for novel therapeutic approaches to ameliorating the symptoms of the PD.
|Faust, Thomas W; Assous, Maxime; Tepper, James M et al. (2016) Neostriatal GABAergic Interneurons Mediate Cholinergic Inhibition of Spiny Projection Neurons. J Neurosci 36:9505-11|
|Ãœnal, Bengi; Shah, Fulva; Kothari, Janish et al. (2015) Anatomical and electrophysiological changes in striatal TH interneurons after loss of the nigrostriatal dopaminergic pathway. Brain Struct Funct 220:331-49|
|Faust, Thomas W; Assous, Maxime; Shah, Fulva et al. (2015) Novel fast adapting interneurons mediate cholinergic-induced fast GABAA inhibitory postsynaptic currents in striatal spiny neurons. Eur J Neurosci 42:1764-74|
|Xenias, Harry S; IbÃ¡Ã±ez-Sandoval, Osvaldo; KoÃ³s, Tibor et al. (2015) Are striatal tyrosine hydroxylase interneurons dopaminergic? J Neurosci 35:6584-99|
|IbÃ¡Ã±ez-Sandoval, Osvaldo; Xenias, Harry S; Tepper, James M et al. (2015) Dopaminergic and cholinergic modulation of striatal tyrosine hydroxylase interneurons. Neuropharmacology 95:468-76|
|Oladapo, Abiola O; Rascati, Karen L (2012) Review of survey articles regarding medication therapy management (MTM) services/programs in the United States. J Pharm Pract 25:457-70|
|English, Daniel F; Ibanez-Sandoval, Osvaldo; Stark, Eran et al. (2012) GABAergic circuits mediate the reinforcement-related signals of striatal cholinergic interneurons. Nat Neurosci 15:123-30|
|Unal, Bengi; Ibanez-Sandoval, Osvaldo; Shah, Fulva et al. (2011) Distribution of tyrosine hydroxylase-expressing interneurons with respect to anatomical organization of the neostriatum. Front Syst Neurosci 5:41|
|Koos, Tibor; Tecuapetla, Fatuel; Tepper, James M (2011) Glutamatergic signaling by midbrain dopaminergic neurons: recent insights from optogenetic, molecular and behavioral studies. Curr Opin Neurobiol 21:393-401|
|IbÃ¡Ã±ez-Sandoval, Osvaldo; Tecuapetla, Fatuel; Unal, Bengi et al. (2011) A novel functionally distinct subtype of striatal neuropeptide Y interneuron. J Neurosci 31:16757-69|
Showing the most recent 10 out of 35 publications